Serum Neurofilament Light (NfL) as a Marker for Brain Injury in

Clinical Trial Summary

The investigators propose that immune effector cell-associated neurotoxicity syndrome (ICANS) is predicated upon the early loss of blood brain barrier (BBB) integrity with subsequent monocyte infiltration leading to cross-activation of native glial cells. Glial overstimulation leads to neuroinflammation, synaptic dysfunction, and ultimately neuronal injury.

See also
Status	Clinical Trial	Phase
Completed	`NCT05510596` - Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome	N/A
Completed	`NCT01399372` - Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma	Phase 2
Completed	`NCT01196442` - Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer	N/A
Completed	`NCT00775645` - S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy	Phase 3
Recruiting	`NCT00884767` - Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin	Phase 2
Recruiting	`NCT03330964` - Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity	N/A
Active, not recruiting	`NCT04150913` - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity	Phase 2
Completed	`NCT01417507` - Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery	N/A
Completed	`NCT00471445` - Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients	Phase 3
Completed	`NCT00365768` - Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors	Phase 2
Withdrawn	`NCT00734773` - Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL	Phase 0
Completed	`NCT00305799` - Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors	N/A
Completed	`NCT00018967` - Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate	N/A
Active, not recruiting	`NCT00978458` - Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma	Phase 3
Completed	`NCT05094154` - Effect of Antibiotic Choice On ReNal Outcomes (ACORN)	Phase 4
Completed	`NCT02486198` - Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer	Phase 3
Not yet recruiting	`NCT05798884` - Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients	N/A
Completed	`NCT02864030` - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment	Phase 4
Completed	`NCT00755313` - Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer	N/A
Completed	`NCT00369564` - Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer	Phase 3

NCT number	NCT04614987
Study type	Observational
Source	Washington University School of Medicine
Contact
Status	Terminated
Phase
Start date	February 25, 2021
Completion date	September 13, 2023

Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms